The work described here was performed at Purdue University. Results were presented in poster form at the 2008 ACVIM Forum.
Antithrombotic Effect of Enoxaparin in Clinically Healthy Cats: A Venous Stasis Model
Article first published online: 11 NOV 2009
Copyright © 2009 by the American College of Veterinary Internal Medicine
Journal of Veterinary Internal Medicine
Volume 24, Issue 1, pages 185–191, January/February 2010
How to Cite
Van De Wiele, C.M., Hogan, D.F., Green, H.W. and Sederquist, K.D. (2010), Antithrombotic Effect of Enoxaparin in Clinically Healthy Cats: A Venous Stasis Model. Journal of Veterinary Internal Medicine, 24: 185–191. doi: 10.1111/j.1939-1676.2009.0412.x
- Issue published online: 4 JAN 2010
- Article first published online: 11 NOV 2009
- Submitted December 10, 2008; Revised July 20, 2009; Accepted September 22, 2009.
Background: Systemic arterial thromboembolic events are a serious complication of cardiac disease in cats.
Objectives: To determine if enoxaparin induces an antithrombotic effect in cats at a dosage of 1 mg/kg SC q12h and if this antithrombotic effect is predicted by anti-Xa activity.
Animals: Fourteen clinically healthy cats were divided into 3 groups: control (4 cats), treated and assessed at 4 hours (5 cats), and treated and assessed at 12 hours (5 cats).
Methods: A venous stasis model was used and the extent of thrombus formation estimated by measuring thrombus weight and accretion of 125I-fibrinogen. Plasma anti-Xa activity was measured in treated cats.
Results: There was a significant reduction in thrombus formation in the 4 h group compared with control (median weight, 0.000 versus 0.565 mg/mm, P < .01; median %125I-fibrinogen accretion, 0.0 versus 42.0%, P < .01). There was a reduction in thrombus formation in the 12 h group (median weight, 0.006 mg/mm, P= .09; median %125I-fibrinogen accretion, 3.83%, P= .09) but this reduction was not significant. The median percent thrombus inhibition for treated cats was 100.0% at 4 hours and 91.4% at 12 hours. Plasma anti-Xa activity was not significantly correlated with thrombus formation.
Conclusions and Clinical Importance: This pilot study demonstrates that enoxaparin, when administered at a dosage of 1 mg/kg SC q12h, produces an antithrombotic effect in a venous statsis model in clinically healthy cats. Furthermore, this study demonstrates that anti-Xa activity is a poor predictor of enoxaparin's antithrombotic effect.